CL2011003052A1 - Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras. - Google Patents
Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras.Info
- Publication number
- CL2011003052A1 CL2011003052A1 CL2011003052A CL2011003052A CL2011003052A1 CL 2011003052 A1 CL2011003052 A1 CL 2011003052A1 CL 2011003052 A CL2011003052 A CL 2011003052A CL 2011003052 A CL2011003052 A CL 2011003052A CL 2011003052 A1 CL2011003052 A1 CL 2011003052A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- treatment
- imidazo
- compound
- pharmaceutical composition
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- KEEQKXYAIZOEPW-UHFFFAOYSA-N 8-(2,4-dimethoxypyrimidin-5-yl)-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CC1=NN(CC)C=C1N1C(=O)N(C)C2=C1C1=CC(C=3C(=NC(OC)=NC=3)OC)=CC=C1N=C2 KEEQKXYAIZOEPW-UHFFFAOYSA-N 0.000 title 1
- 201000009030 Carcinoma Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18414109P | 2009-06-04 | 2009-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011003052A1 true CL2011003052A1 (es) | 2012-08-31 |
Family
ID=42697442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011003052A CL2011003052A1 (es) | 2009-06-04 | 2011-12-02 | Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8476294B2 (OSRAM) |
| EP (1) | EP2438064A1 (OSRAM) |
| JP (1) | JP5596137B2 (OSRAM) |
| KR (1) | KR101445458B1 (OSRAM) |
| CN (1) | CN102574845B (OSRAM) |
| AR (1) | AR076949A1 (OSRAM) |
| AU (1) | AU2010255727B2 (OSRAM) |
| BR (1) | BRPI1010621A2 (OSRAM) |
| CA (1) | CA2763821A1 (OSRAM) |
| CL (1) | CL2011003052A1 (OSRAM) |
| CO (1) | CO6470887A2 (OSRAM) |
| CR (1) | CR20110608A (OSRAM) |
| CU (1) | CU24064B1 (OSRAM) |
| DO (1) | DOP2011000373A (OSRAM) |
| EA (1) | EA020715B1 (OSRAM) |
| EC (1) | ECSP11011500A (OSRAM) |
| GE (1) | GEP20156267B (OSRAM) |
| IL (1) | IL216452A0 (OSRAM) |
| MA (1) | MA33332B1 (OSRAM) |
| MX (1) | MX2011012943A (OSRAM) |
| NI (1) | NI201100209A (OSRAM) |
| NZ (1) | NZ596487A (OSRAM) |
| PE (1) | PE20120224A1 (OSRAM) |
| SG (1) | SG176572A1 (OSRAM) |
| TN (1) | TN2011000626A1 (OSRAM) |
| TW (1) | TWI464168B (OSRAM) |
| UA (1) | UA106074C2 (OSRAM) |
| UY (1) | UY32682A (OSRAM) |
| WO (1) | WO2010139731A1 (OSRAM) |
| ZA (1) | ZA201108439B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| KR20140014104A (ko) * | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| US9284315B2 (en) | 2011-11-17 | 2016-03-15 | Zuanzhu Pharma Co., Ltd. | Three-ring PI3K and/or mTOR inhibitor |
| WO2014141118A1 (en) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
| JP6419783B2 (ja) | 2013-04-15 | 2018-11-07 | エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ | 殺菌・殺カビ性アミド |
| CN105531348B (zh) * | 2013-09-11 | 2017-11-07 | 默克专利有限公司 | 杂环化合物 |
| CN104513254B (zh) | 2013-09-30 | 2019-07-26 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| JP6606428B2 (ja) * | 2013-10-11 | 2019-11-13 | 国立大学法人 東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| CN104447740B (zh) * | 2013-11-20 | 2017-02-22 | 北京富龙康泰生物技术有限公司 | 咪唑酮类衍生物、其药物组合物和用途 |
| NO2714752T3 (OSRAM) | 2014-05-08 | 2018-04-21 | ||
| HRP20181670T1 (hr) | 2014-06-03 | 2018-12-14 | Idorsia Pharmaceuticals Ltd | Spojevi pirazola i njihova uporaba kao blokatora kalcijevih kanala t-tipa |
| HUE054745T2 (hu) * | 2015-04-02 | 2021-09-28 | Merck Patent Gmbh | Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| US10988472B2 (en) | 2016-10-13 | 2021-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for blocking transmission of malarial parasite |
| EP3554490B1 (en) | 2016-12-16 | 2022-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| TWI808960B (zh) | 2017-02-06 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3154475A1 (en) * | 2019-09-23 | 2021-04-01 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| US20230380203A1 (en) * | 2021-01-26 | 2023-11-23 | Boe Technology Group Co., Ltd. | Quantum dot light-emitting device, display apparatus and manufacturing method |
| CN116768928A (zh) * | 2023-06-15 | 2023-09-19 | 上海毕臣生化科技有限公司 | 一种3-叔丁基-5-硼酸酯基吡啶的合成方法 |
| CN117384154A (zh) * | 2023-09-04 | 2024-01-12 | 广州医科大学 | 一种吡咯并喹啉酮化合物、合成方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| BRPI0416801A (pt) | 2003-11-21 | 2007-01-09 | Novartis Ag | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101309687A (zh) | 2005-11-04 | 2008-11-19 | 科勒制药集团公司 | 经羟基和烷氧基取代的1h-咪唑并喹啉及其方法 |
| MX2009005360A (es) | 2006-11-20 | 2009-06-05 | Novartis Ag | Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinol in-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propion itrilo. |
| KR101472607B1 (ko) | 2007-02-20 | 2014-12-15 | 노파르티스 아게 | 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린 |
| PT2182948E (pt) * | 2007-07-24 | 2013-04-30 | Novartis Ag | Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr |
| US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| CA2717948C (en) | 2008-03-26 | 2016-09-06 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| WO2010038165A1 (en) | 2008-09-30 | 2010-04-08 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
-
2010
- 2010-06-02 AU AU2010255727A patent/AU2010255727B2/en not_active Ceased
- 2010-06-02 BR BRPI1010621A patent/BRPI1010621A2/pt not_active IP Right Cessation
- 2010-06-02 UA UAA201114398A patent/UA106074C2/uk unknown
- 2010-06-02 EA EA201101704A patent/EA020715B1/ru not_active IP Right Cessation
- 2010-06-02 EP EP10721029A patent/EP2438064A1/en not_active Withdrawn
- 2010-06-02 CN CN201080034616.0A patent/CN102574845B/zh not_active Expired - Fee Related
- 2010-06-02 JP JP2012513613A patent/JP5596137B2/ja not_active Expired - Fee Related
- 2010-06-02 AR ARP100101942A patent/AR076949A1/es unknown
- 2010-06-02 NZ NZ596487A patent/NZ596487A/xx not_active IP Right Cessation
- 2010-06-02 KR KR1020127000098A patent/KR101445458B1/ko not_active Expired - Fee Related
- 2010-06-02 WO PCT/EP2010/057719 patent/WO2010139731A1/en not_active Ceased
- 2010-06-02 GE GEAP201012484A patent/GEP20156267B/en unknown
- 2010-06-02 MX MX2011012943A patent/MX2011012943A/es active IP Right Grant
- 2010-06-02 MA MA34404A patent/MA33332B1/fr unknown
- 2010-06-02 CA CA2763821A patent/CA2763821A1/en not_active Abandoned
- 2010-06-02 US US12/792,471 patent/US8476294B2/en not_active Expired - Fee Related
- 2010-06-02 PE PE2011002047A patent/PE20120224A1/es not_active Application Discontinuation
- 2010-06-02 SG SG2011085487A patent/SG176572A1/en unknown
- 2010-06-03 UY UY0001032682A patent/UY32682A/es not_active Application Discontinuation
- 2010-06-03 TW TW099117977A patent/TWI464168B/zh not_active IP Right Cessation
-
2011
- 2011-11-17 IL IL216452A patent/IL216452A0/en not_active IP Right Cessation
- 2011-11-17 ZA ZA2011/08439A patent/ZA201108439B/en unknown
- 2011-11-21 CR CR20110608A patent/CR20110608A/es unknown
- 2011-11-30 NI NI201100209A patent/NI201100209A/es unknown
- 2011-11-30 CU CU2011000221A patent/CU24064B1/es not_active IP Right Cessation
- 2011-12-02 DO DO2011000373A patent/DOP2011000373A/es unknown
- 2011-12-02 CL CL2011003052A patent/CL2011003052A1/es unknown
- 2011-12-02 EC EC2011011500A patent/ECSP11011500A/es unknown
- 2011-12-05 TN TNP2011000626A patent/TN2011000626A1/en unknown
- 2011-12-12 CO CO11170918A patent/CO6470887A2/es active IP Right Grant
-
2013
- 2013-05-24 US US13/901,849 patent/US20140005163A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011003052A1 (es) | Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras. | |
| CL2015001818A1 (es) | Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras. | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
| CL2008003200A1 (es) | Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| UY37926A (es) | Formulaciones de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| CL2009000443A1 (es) | Compuestos derivados de 3-metil-imidazo-[1,2-b]-piridazina, moduladores de cinasa de tirosina c-met; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades proliferativas como tumores solidos, metastasis, cancer renal, cancer de cabeza y cuello. cancer pulmon. | |
| CL2009001212A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras. | |
| UA107814C2 (uk) | Спірооксіндольні антагоністи мdм2 | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| CL2012003680A1 (es) | Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| PA8740901A1 (es) | Compuestos organicos | |
| CL2015000337A1 (es) | Compuestos derivados de 2,3-benzodiazepinas sustituidas; compuestos intermediarios; formulacion farmaceutica; uso para la profilaxis y/o terapia de trastornos tumorales tales como leucemias, carcinoma de prostata, carcinoma de mama, melanomas, entre otros y control de fertilidad masculina. | |
| CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
| CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| CL2008001025A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer. | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| HN2011001593A (es) | Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades | |
| CL2013002430A1 (es) | Compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de proteina kinasa trk; composicion farmaceutica; compuesto intermediarios; utiles para el tratamiento de carcinoma pailar de tiroides, cancer de pancreas, cancer de colon y carcinoma de mama, entre otras. | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
| CL2013002870A1 (es) | Sal diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida; método de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento o profilaxis del cáncer. |